Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $135.02 USD
Change Today -7.55 / -5.30%
Volume 210.0
LZAGF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
Singapore
Frankfurt
As of 8:10 PM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

lonza group ag-reg (LZAGF) Key Developments

Lonza Group Ltd. Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2015; Reiterates Earnings Guidance for the Full Year of 2015

Lonza Group Ltd. reported unaudited consolidated earnings results for the six months ended June 30, 2015. For the period, the company reported sales of CHF 1,904 million compared to CHF 1,800 million a year ago. EBIT was CHF 192 million compared to CHF 215 million a year ago. Profit before income taxes was CHF 137 million compared to CHF 174 million a year ago. Profit for the period, attributable to the equity holder of the parent was CHF 111 million or CHF 2.11 per diluted share compared to CHF 140 million or CHF 2.68 per diluted share a year ago. Net cash provided by operating activities was CHF 358 million compared to CHF 163 million a year ago. Purchase of property, plant & equipment and intangible assets was CHF 96 million compared to CHF 70 million a year ago. EBITDA was CHF 375 million compared to CHF 362 million a year ago. Operational free cash flow was CHF 299 million compared to CHF 124 million a year ago. Net debt as at June 30, 2015 was CHF 1,842 million compared to CHF 2,113 million a year ago. Core EBITDA was CHF 391 million compared to CHF 368 million a year ago. Core result from operating activities was CHF 260 million compared to CHF 241 million a year ago. Core profit for the period was CHF 166 million or CHF 3.16 per diluted share compared to CHF 162 million or CHF 3.10 per diluted share a year ago. Core RONOA was 16.1% compared to 14.5% a year ago. RONOA was 9.6% compared to 10.5% a year ago. The company reiterated its full-year 2015 outlook with sales growth in reported currency compared with last year's sales. CORE EBIT growth of at least 5% in constant exchange rates. CAPEX expected to remain below CHF 300 million.

Lonza Group Ltd. Announces Agreement with TAP Biosystems Group plc

Lonza Group Ltd. has reached an agreement with TAP Biosystems Group plc to distribute the company's Real Architecture For 3D Tissue, or RAFT, 3D cell culture system. The RAFT System uses a patented absorber technology to create cell layers in high-density collagen that mimic the in vivo environment. This system enables researchers to generate more biologically meaningful data from their cell culture studies. The versatile RAFT Kit is available in a number of formats and is appropriate for analysis using a wide variety of imaging, biochemical and histological techniques. In combination with Lonza's human primary cells and media solutions, the RAFT 3D Cell Culture System empowers researchers to create physiologically relevant cell culture models for use across drug discovery and research applications. The RAFT 3D Cell Culture System has been designed with simple, easy-to-follow protocols that allow researchers to set up 3D cell cultures in under an hour. The RAFT Kit includes a collagen type I solution and biocompatible absorbers, which remove the medium from cell-seeded collagen hydrogels and allow researchers to control both cell concentration and matrix density. RAFT 3D Cell Culture System is a flexible system that supports a variety of formats including 24-well, 96-well and insert-well. The key differentiation of the RAFT System from other platforms is its versatility. This system can be utilized with one cell type, or multiple cell types in parallel. Cells can be cultured within the collagen scaffold, or on top, or both. The addition of permeable membrane cell culture inserts provides other extensions to the system, allowing the generation of barrier models including air-lift models. Furthermore, the system is compatible with a variety of cell types and has already been used to successfully generate 3D cultures in a number of research areas, including oncology, toxicology and neuroscience.

Lonza Group Ltd, H1 2015 Earnings Call, Jul 22, 2015

Lonza Group Ltd, H1 2015 Earnings Call, Jul 22, 2015

Lonza Group Ltd. and Octane Biotech Inc. to Evaluate Octane Cocoon Cell Production Platform

Lonza Group Ltd. and Octane Biotech Inc. have agreed to enter into an exclusive technology evaluation of the Octane Cocoon cell production platform for personalized cell therapy manufacturing. Unlike current, labor-intensive production methods, the Octane Cocoon has the potential to enable the automated manufacturing of patient-specific cell therapies for maximum efficiency, traceability and scale-up. Under the terms of the agreement, Lonza will evaluate the Octane Cocoon platform for autologous cell therapy products.

Lonza Group Ltd Signs New Long-Term Product Supply Agreement with Alexion

Lonza Group Ltd. announced the signing of a new long-term product supply agreement with Alexion. Under the agreement Lonza will construct and launch a new suite dedicated to Alexion manufacturing. Lonza will own and operate the suite as part of its Portsmouth, NH (USA) site. This contract is an expansion of an existing manufacturing agreement. This agreement will supplement existing production of Alexion products at multiple Lonza facilities. The expansion of the existing site in Portsmouth, near Boston, MA (USA), will provide valued customers increased access to Lonza's proven biological manufacturing and regulatory expertise, experienced global workforce and high level of focused customer service. Lonza has more than two decades of worldwide manufacturing experience with mammalian biotherapeutics.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LZAGF:US $135.02 USD -7.55

LZAGF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Ashland Inc $104.65 USD -0.34
Clariant AG SFr.17.54 CHF -0.06
Croda International PLC 2,892 GBp +42.00
Owens Corning $44.03 USD -0.43
PerkinElmer Inc $49.48 USD +0.04
View Industry Companies
 

Industry Analysis

LZAGF

Industry Average

Valuation LZAGF Industry Range
Price/Earnings 31.8x
Price/Sales 1.8x
Price/Book 3.4x
Price/Cash Flow 32.2x
TEV/Sales 1.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LONZA GROUP AG-REG, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.